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Gold nanoparticle (AuNP) physicochemical characteristics, mainly size and charge, modulate their biodistribution, cytotoxicity,
and immunorecognition as reported from in vitro and in vivo studies. While data from in vitro studies could be biased by
several factors including activation of cells upon isolation and lack of sera proteins in the microenvironment of primary
generated cell lines, in vivo studies are costly and time-consuming and require ethics consideration. In this study, we developed
a simple and novel in vivo-like method to test for NP immunorecognition from freshly withdrawn human blood samples.
AuNPs with a size range of 30± 5 nm coated with cationic poly(L-lysine) (PLL) dendrigraft and slightly negative poly(vinyl
alcohol) (PVA) were synthesized in water. PLL-capped AuNPs were further coated with poly(ethylene glycol) (PEG) to obtain
nearly neutrally charged PEG-AuNPs. Physicochemical properties were determined using zeta potential measurements, UV-Vis
spectroscopy, dynamic light scattering (DLS), and scanning electron microscopy (SEM). Gel electrophoretic separation, zeta
potential, and DLS were also used to characterize our NPs after human blood plasma treatment. PLL-AuNPs showed similar
variation in charge and binding aﬃnity to plasma proteins in comparison with PVA-AuNPs. However, PLL-AuNPs.protein
complexes revealed a drastic change in size compared to the other tested particles. Results obtained from the neutrophil function
test and pyridine formazan extraction revealed the highest activation level of neutrophils (~70%) by 50μg/mL of PLL-AuNPs
compared to a null induction by PEG- and PVA-AuNPs. This observation was further veriﬁed by ﬂow cytometry analysis of
polymorphonuclear cell size variation in the presence of coated AuNPs. Overall, our in vivo-like method, to test for NP
immunorecognition, proved to be reliable and eﬀective. Finally, our data supports the use of PEG-AuNPs as promising vehicles
for drug delivery, as they exhibit minimal protein adsorption aﬃnity and insigniﬁcant charge and size variation once introduced
in whole blood.
1. Introduction
In the dawn of a new era of biomedical advancements, nano-
technology has paved the way to manipulate and tailor
matters at the nanometer scale, which permits the engineering
of a wide array of nanomaterials [1, 2]. Engineered nanoparti-
cles (NPs), particularly gold nanoparticles (AuNPs), are one
of the most commonly studied substances due to their wide-
spread use in biomedical applications, cosmetics, and cancer
treatment [3–7]. AuNPs exhibit attractive physicochemical
and optical properties, fast biodistribution, and dose-
dependent cytotoxicity [8–11]. However, for eﬀective clinical
applications, AuNPs should evade the ﬁrst line of innate
immunity mediated particularly by polymorphonuclear cells
(PMNs) [12, 13].
Therefore, NPs must be well designed and properly
coated to cross the immune barrier and ensure optimum traf-
ﬁcking to a targeted site with minimal cytotoxicity [14, 15].
The immunogenic eﬀects of nanoparticles are mainly attrib-
uted to their charge, size, and type [16–18]. In alignment with
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this observation, Hwang et al. [19] mentioned that the
inﬂammatory immune responses are largely dependent on
the nature of cationic additives in nanosystems. Lockman
et al. [20] demonstrated that cationic carbon NPs exert toxic-
ity at the blood brain barrier while anionic and neutral NPs
did not. Furthermore, Moyano et al. [21] showed that neutral
tetraethylene glycol (TEG) AuNPs do not elucidate inﬂam-
matory responses in an in vivo mouse model. Bartneck
et al. [22] highlighted the fact that charge rather than size
aﬀects the capacity of NPs to be trapped. For instance,
positively charged CTAB-coated gold nanorods (NRs) sig-
niﬁcantly enhanced cellular uptake by neutrophils, while
negatively charged PEO-NRs did not [22]. Thus, CTAB
NRs might not escape the inﬂammatory response by phago-
cytes prior to their extravasation to the target site for their
ligand release.
On the other hand, nanomaterials of diﬀerent morphol-
ogies, such as carbon nanotubes, yet of similar composition
exhibit diﬀerent biological responses regarding inﬂammation
and injury to cells, concomitant to macrophage and neutro-
phil accumulation [23]. It was also reported that colloidal
AuNPs injected into mice enhanced the proliferation of lym-
phocytes [9]. Other studies revealed size-dependent uptake
and cytokine release of bare AuNPs by human dendritic cells
[24]. Moreover, AuNPs at sizes ranging from 15 to 50 nm
might undergo phagocytosis by monocytes and trapping via
neutrophil extracellular traps (NETs) [22]. In addition, even
smaller sizes of AuNPs (5 to 35nm) showed in vitro internal-
ization by human leukemia macrophages [25].
As noted above, NP immunorecognition can be moni-
tored using diﬀerent methods, such as lymphocyte prolifera-
tion, neutrophil function test (NFT) [26], NET formation,
cytokine release, phagocytosis/internalization activity, and
sera antibody measurements [27–31]. Methods can be
conducted in vitro or in vivo using animal models. In vitro
studies mainly depend on the isolation of primary cell lines
or the utilization of immortal transformed cell lines [32–35].
However, such cell lines do not mimic in vivo physiological
conditions and might result in false-positive observations
due to the activation of immune cells during isolation or the
lack of sera proteins that might aﬀect immune recognition
via opsonization [36–38]. In vivo studies, on the other hand,
are quite expensive, complex in their experimental setup,
and time demanding and require a high level of ethics consid-
eration [14, 39]. Given that slight changes to the coating and
size of AuNPs might elicit diﬀerent immune responses, we
employed an in vivo-like method that is rapid, reliable, and
cheap to investigate the interaction of the phagocytes, partic-
ularly neutrophils, with various charged polymer-capped
AuNPs, namely, with cationic poly(L-lysine) (PLL) dendri-
graft, slightly negative poly(vinyl alcohol) (PVA), and nearly
neutral poly(ethylene glycol) (PEG) coats with the aim of
strengthening our knowledge on charged AuNPs and their
eﬀect on immune cells. Finally, we speculate based on pre-
vious results and other reports that loading AuNPs with
polymers such as PEG and PVA would create a stable pro-
tective hydrophilic layer that reduces their recognition and
uptake by PMNs and enhances their longevity in circulation
[40–44]. However, cationic PLL-AuNPs will trigger a
pronounced immune response since positively charged
polymers have the tendency to bind to negatively charged
membranes triggering activation and endocytosis [45, 46].
In our study, the properties of PLL-, PVA-, and PEG-
coated AuNPs were characterized using zeta potential
measurements, UV-Vis spectroscopy, dynamic light scatter-
ing, and scanning electron microscopy. To address the
immunogenicity of NPs, we investigated the activation eﬃ-
ciency of neutrophils by charged NPs using nitrotetrazolium
blue (NBT) dye reduction and pyridine extraction of forma-
zan granules from a freshly withdrawn human blood sample.
Flow cytometry was used to conﬁrm the morphological
changes upon neutrophil activation with charged AuNPs.
In contrast to what is already reported in the literature,
AuNPs—if coated with PVA or PEG—can resist phagocyto-
sis, serving as potential noncytotoxic vehicles in medical and
healthcare applications.
It is worth noting that the surface charge of our tested
NPs might be aﬀected by plasma protein adsorption upon
incubation with human whole blood, consequently altering
the size of the polymer-AuNPs.protein complexes. This
notion is addressed in ourmanuscript in an attempt to under-
stand whether the surface charge has a direct or indirect eﬀect
in neutrophil NPs’ recognition.
2. Materials and Methods
2.1. Chemicals. Puriﬁed H2O (resistivity ≈ 18 2 MΩ·cm)
was used as a solvent. All glassware was cleaned with aqua
regia (3 parts of concentrated HCl and 1 part of concentrated
HNO3), rinsed with distilled water, ethanol, and acetone, and
oven dried before use. Tetrachloroauric acid trihydrate
(HAuCl4, 3H2O), L-ascorbic acid, phorbol myristate acetate
(PMA), nitrotetrazolium blue (NBT), poly(vinyl alcohol)
(PVA), and thiolated pyridine were purchased from Sigma-
Aldrich. Thiol-terminated poly(ethylene glycol) methyl
ether, Mw =5400, was purchased from Polymer Source.
Poly(L-lysine) (PLL) dendrigraft with an average molecular
weight of 7KD was synthesized and characterized by a previ-
ously reported method [47]. Red blood cell lysis buﬀer was
purchased from Partec. All chemicals were used as received
without further puriﬁcation.
2.2. Synthesis of Charged Gold (Au) Nanoparticles
2.2.1. Synthesis of PLL-AuNPs. In a 50mL round ﬂask con-
taining 22.07mL of deionized water, 0.336mL HAuCl4
(18.6mM)was added under stirring, followed by the fast addi-
tion of 2.5mL of PLL (100μM) as a stabilizing ligand and
0.097mL of ascorbic acid (0.1M) as a reducing agent. After
addition of ascorbic acid, the color of the solution changed
from pale yellow to red. The solution was kept under stirring
for 24 hours. The obtained nanoparticles have a hydronamic
diameter of about 47.5± 0.3 nm (size by intensity) and a zeta
potential of +33± 2.5mV.
2.2.2. Synthesis of PVA-AuNPs. In a 50mL round ﬂask con-
taining 24.07mL of deionized water, 0.336mL HAuCl4
(18.6mM) was added under stirring, followed by the fast
addition of 0.5mL of PVA (0.091% w/v) as a stabilizing
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ligand and 0.097mL of ascorbic acid (0.1M) as a reducing
agent. After addition of ascorbic acid, the color of the solu-
tion changed from pale yellow to deep red. The solution
was kept under stirring for 24 hours. The obtained nano-
particles had a hydronamic diameter of about 59.0± 6.0 nm
(size by intensity) and a zeta potential of −9± 1mV.
2.2.3. Synthesis of PEG-AuNPs by PEGylation of PLL-AuNPs.
To 5mL of PLL-AuNP colloidal solution under stirring,
0.27mL of SH-PEG5000 (111μM) was added drop wise dur-
ing 3mins and the solution was kept under stirring for two
hours. The successful PEGylation was conﬁrmed by DLS
where the size of the PLL-AuNPs was found to increase from
47.5± 0.3 nm (size by intensity) to 75.26± 0.76 nm while the
zeta potential was found to decrease from +33± 2.5mV
to +12.0± 3mV, conﬁrming the attachment of PEG onto
the PLL-AuNP surface.
2.3. Avoiding Endotoxin Contamination. Due to the ubiqui-
tous presence of endotoxin in all chemicals and glassware
used in laboratories [48] and its interference in immunosaf-
ety results [49], appropriately adopted practices were taken
into consideration for avoiding/restricting endotoxin con-
tamination [50]. Eﬀective methods included working under
laminar ﬂow hood with gloves and autoclaved glasses after
cleaning with aqua regia and ethanol; moreover, deionized
water was double autoclaved and nonpyrogenic plastics were
used similarly for all sample preparation. We believe that
such practices are safer than dry heating our NPs at high
temperatures as the latter might aﬀect the AuNP physico-
chemical characteristics [51].
2.4. Scanning Electron Microscopy (SEM). Gold nanoparticles
were deposited from solution on a silicon wafer and dried in
air prior to inspection by scanning electron microscopy
(SEM). The samples were inspected using a Hitachi S-4300
environmental scanning electronmicroscope (ESEM) operat-
ing at 10 kV. Samples were metalized with carbon to avoid
charging during observation.
2.5. Dynamic Light Scattering and Zeta Potential
Measurements. The size distribution and surface charge (zeta
potential) of the AuNP colloidal solutions were determined
by dynamic light scattering (DLS) with the Malvern Zetasizer
Nano ZSP using the default NIBS 173° backscattering tech-
nique. The model used in the ﬁtting procedure was based on
Mark–Houwink parameters; all the data was ﬁtted using the
cumulative ﬁt given by the suppliers.Measurements were per-
formed on the pristine solutions of AuNPs (50μg/mL) using
disposable folded capillary cuvettes at 25°C. Triplicates of
each sample have been made for result comparison eﬃciency.
2.6. Incubation of AuNPs with Human Blood Plasma.Human
blood was collected intravenously from three diﬀerent
individuals (n = 3) and collected in either EDTA or lithium
heparin tubes to prevent coagulation. Blood samples were
centrifuged at 1000 g for 5mins to allow the serum to sepa-
rate. After centrifugation, human serum was incubated with
3 diﬀerently charged AuNPs (50μg/mL) (PLL, PVA, and
PEG) at a 1 : 1 ratio at 37°C for 15mins. The samples were
then centrifuged at 8000 rpm for 10mins to pellet down the
AuNPs.protein complexes. The excess serum was removed,
and the pellet was washed 3 times then resuspended in
deionized water.
2.7. DLS and Zeta Measurements of AuNPs.protein
Complexes. 500μL of each AuNPs.protein complex was
withdrawn for DLS and zeta measurements. The readings
were done in triplicate for statistical signiﬁcance and were
compared with the previous readings of AuNPs prior to
plasma incubation.
2.8. 1-D Gel Electrophoresis. A 12% SDS-polyacrylamide gel
was prepared. The samples were pelleted down after washing
and were resuspended with an SDS buﬀer at a concentration
of 50μg/mL containing 2% SDS, 5% β-mercaptoethanol,
10% glycerol, and 62.5mM Tris-HCl. After heating at 95°C
for 5mins, 20μL of each sample was transferred to each well
of the previously prepared gel, with human serum (1 : 1000)
being a control. Gels were run at a constant voltage of
200V for 45mins and stained using a solution of Coomassie
Blue protein stain. Gels were imaged with ChemiDoc-It
Imaging System using VisionWorks LS analysis software.
2.9. Neutrophil Function Test and Microscopic Examination.
1mL of whole human blood was withdrawn via intravenous
injection and stored in EDTA tubes. 100μL of blood was
transferred to an eppendorf tube containing 50μL of
1mg/mL NBT (nitrotetrazolium blue) and 50μL of diﬀer-
ently charged AuNPs (50μg/mL) or with PMA as a positive
control. The mixture was then incubated at 37°C for 15mins.
Smears where then ﬁxed using 1mL ice-cold methanol and
left to dry at room temperature. Finally, smears were stained
using the Wright’s stain technique (eosin-methylene blue)
and observed under a light microscope at 40x and 100x.
2.10. Preparing Cells for Flow Cytometry Analysis. 100μL of
EDTA whole blood was transferred to a FACS cuvette
containing 50μL of 1mg/mL NBT dye and 50μL of one of
the charged AuNPs (50μg/mL). PBS and PMA served as a
negative control and positive control, respectively. Samples
were then incubated at 37°C for 15mins. In addition,
100μL of 4% PFA was added to all samples which have been
left to incubate in the dark for another 10mins. Finally, the
volume of the samples was brought up to 1mL using 1x
PBS (700mL). Samples were read using a Partec Cube 8 ﬂow
cytometer with gates set at 2 × 105 particles, and data was
analyzed using FlowJo.
2.11. Pyridine Extraction and Spectrophotometry. Pyridine
extraction was done using the same protocol adopted for
FACS analysis. 100μL of blood was used for each sample
mixed with 50μL of one type of the charged AuNPs
(50μg/mL) PLL, PVA, and PEG and 50μL of 1mg/mL
NBT. Samples were then incubated at 37°C for 15mins, ﬁxed
with 4% PFA, and incubated with RBC lysis buﬀer for
20mins. Afterwards, samples were centrifuged at 400 g for
10mins, the supernatant was discarded, and the pellet was
resuspended with 0.5mL of 99% pyridine and 0.5mL
1 × PBS to extract formazan deposits. Formazan absorbance
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was measured at 515nm using a SPECORD 250 PLUS
spectrophotometer. Finally, data measurements were nor-
malized using a basic statistical formula where the normal-
ized value z = xi −min x / max x −min x , where
min x corresponds to lowest value of the PBS data set and
max x corresponds to the highest value of the PMA data
set and xi stands for the value to be normalized. The results
were plotted using EXCEL [52].
2.12. Statistical Analysis. The data are reported as means±
SEM and were analyzed by one-way ANOVA, and diﬀer-
ences between tested groups and control were assessed by
post hoc and Tukey’s test. Statistical signiﬁcance was estab-
lished at p < 0 05, and each experiment was performed and
validated at least three times. Signiﬁcance was reported on
each graph with ∗ representing a p value< 0.05, ∗∗ repre-
senting a p value less than 0.01, and ∗∗ ∗ representing a
p value less than 0.001. NS corresponds to nonsigniﬁcant
diﬀerence.
2.13. Ethics Statement. This study is in compliance with
the recognized international standards and principles of
the Declaration of Helsinki and has received ethical
approval from the institutional review board (IRB) at
Notre Dame University with the following reference number:
IRBSU17_1_FNAS.
3. Results and Discussion
3.1. Synthesis and Characterization of Charged AuNPs.
Gold nanoparticles were synthesized in water at room
temperature through the chemical reduction of gold precur-
sor (HAuCl4.3H2O) with a mid-reducing L-ascorbic acid. In
order to avoid uncontrolled increase in the size and to
achieve a high stability of the resulting nanoparticles, PLL
and PVA were added during the synthesis. The added poly-
mers adsorb onto the growing AuNPs’ surfaces and therefore
allow their ﬁnal size stabilization and surface charge
modiﬁcation. The obtained AuNPs prepared in this study
were characterized by UV-visible absorption spectroscopy
(Figure 1(a)) and SEM (Figure 1(b)). The UV-visible
spectra clearly show a single plasmon absorbance band
characteristic of highly stable spherical AuNPs; the wave-
lengths of maximum absorbance (λmax) were found to be at
522 nm for PVA-AuNPs and 524nm for PLL-AuNPs, indi-
cating that their AuNP core sizes are very close to 30±
5nm as determined by ImageJ analysis of the SEM image of
PLL-AuNPs represented in Figure 1(b). Furthermore, thio-
lated polyethylene glycol (SH-PEG) is well known to further
improve the biocompatibility of the nanoparticles; the
SH-PEG (Mw 5400 g/mol) polymer was grafted onto Au
nanoparticles through Au-SH chemical bonding. PEG
attachment to the nanoparticles via ligand exchange causes
a very slight red shift of about 3 nm in the plasmon absorp-
tion band as shown in the inset of Figure 1(a), and this shift
is mostly due to a change of the dielectric constant at the
nanoparticle surface [53].
The successful PEGylation of PLL-AuNPs was further
proven by dynamic light scattering analysis and zeta potential
measurements. The physicochemical properties, namely, the
size by intensity, number, volume, and Z average of the colloi-
dal AuNPs, were determined using DLS. The polydispersity
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Figure 1: (a) UV-visible spectra of diﬀerent AuNPs synthesized in this study (absorbance adjusted to the same value); the inset shows the
clear red shift of about 3 nm before and after PEGylation of PLL-AuNPs. (b) SEM image of PLL-AuNPs with a diameter of about 30 nm
(scale bar 500 nm).
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index (PDI) and the resulting zeta potential from measure-
ments were also noted as shown in Table 1. Figure 2 shows
the size distribution by intensity (Figure 2(a)) and the zeta
potential measurements of the corresponding colloidal solu-
tions (Figure 2(b)). In brief, DLS measurements have shown
that the synthesized AuNPs were nearly monodisperse with
a single size distribution as shown in Figure 2(a). Further-
more, PLL-AuNPs showed a positive zeta potential of
+33.8± 2.5mV, indicating that they were successfully
coated with PLL. The PDI of the PLL-AuNPs was found
to be 0.115± 0.003, and the Z average was 42.5± 0.3 nm.
The size from DLS was shown to be larger than the one
from SEM; this is due to the fact that the total hydrody-
namic diameter of PLL-AuNPs is measured by DLS, while
in SEM, the AuNPs’ core is only measured. Similarly,
PVA-coated nanoparticles had a Z average diameter of
54.08± 2.58 nm and a polydispersity index (PDI) of 0.288±
0.011, slightly larger than PLL-AuNPs; indeed, their core
sizes were not diﬀerent. This is not surprising as the PVA
molecular weight used in this study was larger and more
polydispersed (13 to 30KD) while that of PLL is smaller
(7KD); PVA-AuNPs show a zeta potential of −9.72±
1.33mV. We should note that the size distribution by num-
ber was the closest to the size of the nanoparticles by SEM.
PEGylation of the PLL-AuNPs was shown to increase the Z
average of the PLL-AuNPs by about 22nm (64.32±
1.22 nm), indicating that SH-PEG was successfully grafted
onto the AuNP surface. Moreover, a decrease of the zeta
potential by about 21mV (+12± 3mV) was also observed,
further proving the successful attachment of PEG onto the
PLL-AuNP surface.
3.2. Incubation of Polymer-Coated AuNPs with Plasma. In
order to assess the plasma protein adsorption onto the diﬀer-
ent charge polymer-coated gold nanoparticles, 50μg/mL of
AuNP polymer solutions was incubated with human serum
(HS) at a ratio of 1 : 1 for 15mins at 37°C. Afterwards, the size
distribution and the zeta potential were recorded. The size
distribution by intensity for the diﬀerent AuNP polymer
solutions was obtained from DLS measurements as shown
in Figure 3(a). There is a clear evidence that the non-
PEGylated positively charged PLL-AuNPs increased enor-
mously from 47.5± 0.3 nm to >200nm, indicating therefore
a strong interaction with plasma proteins. In contrast,
nearly neutral PEGylated PLL-AuNPs increased only
slightly (about 13nm), indicating that the poly(ethylene
glycol) layer plays a role in reducing or inhibiting the plasma
protein adsorption onto PLL-AuNPs. The slightly negatively
charged PVA-AuNPs were also shown to increase by about
80 nm after serum incubation. The zeta potential analysis
after incubation shown in Figure 3(b) also demonstrated that
PLL-PEG-AuNPs and PVA-AuNPs expressed a very slight
change (~6mV) in comparison to non-PEGylated posi-
tively charged PLL-AuNPs that was found to decrease from
+33.8± 2.5 to +3± 0.2mV. Next, we ran a 1-D gel electropho-
resis to identify whether the physicochemical changes are
mediated via protein adsorption on the surface of the NPs.
Electrophoretic separation of plasma proteins from our
Table 1: DLS and zeta potential characterization results of PLL-, PEG-, and PVA-AuNPs.
Type of NP
Z average
(d.nm)
Size by intensity
(d.nm)
Size by number
(d.nm)
Size by volume
(d.nm)
PDI
Zeta potential
(mV)
PLL-AuNP 42.5± 0.3 47.5± 0.3 31.0± 0.7 36.5± 0.50 0.115± 0.003 +33.8± 2.5
PEG-AuNP 64.3± 1.2 75.3± 0.76 38.96± 0.9 49.5± 0.98 0.175± 0.021 +12.0± 3
PVA-AuNP 54.1± 2.6 59.0± 6.0 35.85± 1.8 42.51± 5.1 0.288± 0.011 −9.0± 1.0
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Figure 2: (a) Size distribution by intensity of PVA-AuNPs, PLL-AuNPs, and PLL-PEG-AuNPs from DLS measurements. The size of
PLL-AuNPs increases from 47 nm to 75 nm after PEGylation. (b) Zeta potential for the corresponding AuNP polymers. As shown,
PVA-AuNPs were slightly negative (−10mV), while PEGylation decreased the zeta potential of the positively charged PLL-AuNPs
from +34mV to +12mV.
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polymer-coated NPs showed comparable adsorption of
proteins on PVA and PLL nanoparticles (Figure 3(c));
however, minimal binding of plasma proteins was detected
on PEG particles.
We can conclude that PEGylation of positively charged
PLL-AuNPs did not only decrease their zeta potential but
also pulled oﬀ plasma protein adsorption resulting in very
low neutrophil activation as demonstrated in Figure 4, mak-
ing them suitable for in vivo application.
3.3. Neutrophil Function Test (NFT) and Microscopic
Examination. To determine the behavior of our synthesized
AuNPs under physiological conditions, we ought at testing
their eﬀect on freshly withdrawn whole blood sample. We
assumed that such an environment mimics in vivo physiolog-
ical conditions, rather than working with isolated neutro-
phils. The activation of PMNs, particularly neutrophils, was
visualized under the microscope by monitoring the reduction
of the NBT dye as depicted in Figure 4. NBT is a colorless/
slightly yellow dye that is often used in standard neutrophil
activation tests. It is used to quickly and easily calculate the
percentage of activated neutrophils in peripheral blood
[54]. Upon incubation with the presence of a neutrophil-
activating substance, such as phorbol myristate acetate
(PMA), NBT is reduced by the NADPH oxidase pathway in
neutrophils becoming dark blue-grey in color. This change
in color is due to the reduction of NBT to formazan deposits
[55, 56]. In the present paper, basic light microscopy was used
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Figure 3: (a) Size distribution by intensity of AuNP polymer (50 μg/mL) from DLSmeasurements after incubation in human serum (HS) at a
ratio of 1 : 1 for 15mins at 37°C; the results demonstrate that the PEGylated PLL-AuNP size was the least aﬀected by serum protein adsorption
(13 nm increase only), while the non-PEGylated PLL-AuNPs increased enormously (more than 150 nm), indicating a strong interaction with
plasma protein; PVA-AuNPs were also shown to increase by about 80 nm. (b) Zeta potential measurements on the corresponding AuNP
polymers show that the charge of PVA-AuNPs and PLL-PEG-AuNPs witnessed a very slight change in comparison to non-PEGylated
PLL-AuNPs that was found to decrease from +33.8± 2.5 to +3± 0.2mV. (c) 1-D gel electrophoresis of diﬀerently charged AuNPs after
incubation with human serum. A 12% SDS gel was used to visualize the diﬀerence in serum protein adsorption on charged nanoparticles.
Plasma proteins at 0.1% and 1% were used for comparison. Given that human serum was undiluted during incubation, the amount of
plasma serum proteins adhered to the polymer-coated nanoparticles is relatively low compared to 0.1% plasma proteins alone.
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to identify the amount of formazan deposits in the cytoplasm
of neutrophils, hence deducing their percent activation.
To quantify the percent of activation, formazan
deposits were observed from three diﬀerent experiments.
In Figure 5, NFT results revealed that almost 70% of neu-
trophils were activated in the presence of PLL compared
to 75% as activated by PMA. Activated neutrophils are
clearly observed by the dark blue staining of the formazan
granules deposited inside the cells and those that have
been scattered and released extracellularly, while the per-
cent of activation drastically dropped to almost 3 to 5%
in the presence of negatively or neutrally charged linkers,
such as PVA and PEG (Figure 5).
3.4. Flow Cytometry Analysis of Cellular Activation by
AuNPs.To validate the subjectiveNFT results, ﬂow cytometry
analysis was selected to monitor the size increase in activated
PMNs upon NP treatment. To avoid reading aggregated cells,
PBS PMA
PLL
PVA PEG
Inset
Figure 4: Microscopic observation of AuNP interaction with human neutrophils. Whole blood was withdrawn intravenously from a 22-year-
old adult in a healthy condition. Blood was mixed with EDTA (1 : 1 ratio) prior to its incubation with diﬀerent charged NPs for 15mins at
37°C in the presence of nitro blue tetrazolium (NBT) dye. Cells were then smeared and stained with eosin and methylene blue and
observed under light microscopy. The cell density of polymorphonuclear (PMN) cells was relatively similar in both thick and thin smears,
regardless of erythrocytes’ concentration. Black arrows point to PMNs. PBS: negative control; PMA positive control; poly(L-lysine) (PLL):
positively charged NPs; poly(vinyl alcohol) (PVA): negatively charged NPs; poly(ethylene glycol) (PEG): neutral NPs. Activated
neutrophils exhibited formazan granules in the presence of PMA and PLL as further depicted in the enlarged inset. Scale bar: 10 μm (n = 6).
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Figure 5: Neutrophil activation by various NPs. Positively charged
PLL-AuNPs showed similar activation eﬃcacy of neutrophils as
compared to the control stimulant, PMA, with ~70% of activated
neutrophils forming formazan deposits. PVA- and PEG-coated
NPs only exhibited a 10% activation level with nonsigniﬁcant (NS)
p values compared to PBS. ∗∗∗p value< 0.001 (n = 4).
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PMNs were electronically gated based on large FSC and SSC
signals and the cell density was set to 2 × 105 cells/mL. Such
a cell density minimizes cell-cell adhesion that could not be
analyzed through ﬂow cytometry [12]. Histograms revealed
remarkable increase in the cell volume as marked by an
increase in the forward scatter of the PMA-stimulated cells.
Similarly, cells treated with PLL-AuNPs showed signiﬁcant
increase in cell size as comparedwith unstimulated cells, while
FSC intensity remained insigniﬁcant for cells treated with
PEG and PVA-NPs (Figure 6(a)). For better quantiﬁcation,
mean FSC± SEM derived from three diﬀerent experiments
was plotted in a bar chart (Figure 6(b)).
3.5. Formazan Granule Extraction by Pyridine. In an attempt
to better analyze our results, our data set was normalized
using the formula described in Materials and Methods and
the percent absorbance was calculated for all samples. The
experiment was repeated three times, and a blank containing
a 1 : 1 ratio of deionized water (DIW) and 99% pyridine was
used as a reference. As shown in Figure 7, samples incubated
with PMA showed the highest percent absorbance of about
74%, followed by PLL-AuNPs with 45%. On the other hand,
samples incubated with PVA-AuNPs and PEG-AuNPs dis-
played a percent absorbance of 12% and 14%, respectively.
These values are slightly higher despite being insigniﬁcantly
diﬀerent to the 5% activation level pertained to the control
PBS sample.
Upon exploring the interaction of NPs with the immune
system’s constituents, one should bear in mind many param-
eters such as the model organism being studied, the route of
NP traﬃcking delivery, dose of NPs administered, and time
of exposure. It is highly advisable to avoid long-term
exposure and high concentrations as they can prove to be
cytotoxic and induce apoptosis [57]. In order to avoid such
limitations, we applied an in vivo-like simple and novel
method that mimics physiological conditions. We believe
that our method of incubating AuNPs, or any type of NP,
with whole blood and observing nanoimmunogenicity either
through formazan formation by neutrophils or through
PMNs activation is a straightforward technique that scien-
tists should opt for prior to actual in vivo studies.
Immune cells or leukocytes are mostly composed of
neutrophils, as ﬁrst responders to infections. They are also
known to be powerful and eﬃcient phagocytes [58]. The
FSC :: FSC
100
6.0K
4.0K
Co
un
t
2.0K
0
101 102 103 104
PMA
Sample name
PLL
PVA
PEG
PBS
(a)
0
200
400
600
800
1000
1200
1400
PBS PMA PLL PEG PVA
FS
C 
in
te
ns
ity
Nanoparticle charge
Mean FSC intensity
NS NS
⁎⁎⁎
(b)
Figure 6: FACS analysis of whole blood samples in the presence of charged AuNPs. Whole blood was intravenously extracted and incubated
with PBS, PMA, or various AuNPs (PLL, PVA, and PEG) at 37°C for 15mins. Samples were then analyzed using ﬂow cytometry. (a) Forward
scatter (FSC) distribution of gated PMNs plotted using a logarithmic scale. A representative histogram with an increased FSC signal for PMA
and PLL. This increase in cellular size most likely indicates the activation of polymorphonuclear cells, including neutrophils. Plots were gated
at 200,000 cells per sample and extracted using FlowJo. (b) Bar chart of three replicas depicting nonsigniﬁcant (NS) p values for PEG and PVA
compared to PBS. ∗∗∗ depicts a signiﬁcant activation by PLL compared to PBS with a p value< 0.001.
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Figure 7: Determination of formazan formation after treatment of
whole blood with various AuNPs. As part of neutrophil activation,
formazan formation was extracted using 99% pyridine and
quantiﬁed using UV-Vis spectrophotometry. The bar chart depicts
highest formazan absorbance with PMA followed by PLL and
insigniﬁcant absorbance with PVA and PEG (n = 3). ∗∗ ∗ depicts a
signiﬁcant activation by PLL compared to PBSwith a p value< 0.001.
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neutrophil’s lipid bilayer is ﬂexible enough to undergo certain
complex processes mediated by many intricate mechanisms
such as “intracellular signaling cascades and many cyto-
skeletal rearrangements,” engulﬁng any non-self-particle or
microbe. This occurs upon ligation of neutrophil’s opsonic
receptors, initiating phagocytosis and ROS generation [59].
Another process exhibited by neutrophils is called “NETosis,”
during which the latter expels extracellular DNA traps con-
sisting of histones, granule proteins, and free chromatin
[60]. Thus, monitoring neutrophil activity in the presence of
NPs reﬂects the tolerance of the immune system to foreign
particles prior to their delivery to targeted sites.
In our study, positively charged AuNPs showed the high-
est activation level of neutrophils as observed by NBT reduc-
tion to dark blue formazan deposits. This correlates with a
study conducted by Durocher et al. [61], demonstrating that
positively charged gold nanoparticles proved to be more
proinﬂammatory than negatively charged AuNPs.
The most common technique to assess NBT reduction
is through normal light microscopy observation. However,
such a technique is usually subjective as it relies on the
operator’s perspective and on a nonautomated mode of
counting. Alternatively, we used the pyridine method to
extract formazan deposits and quantify by spectrophotom-
etry their absorbance at 515nm [62]. In fact, it is believed
that formazan deposits absorb and scatter light upon exci-
tation [63]. Our results prior to normalization were lim-
ited by the ability of detecting the absorbance of the free
roaming/nonphagocytosed gold NPs that are known to
absorb light between 500 and 560nm [64]. Another limita-
tion was related to the optical absorbance of hemoglobin
or oxyhemoglobin between 500 and 600nm as a result of
some leftover lysed RBCs in the sample preparation [65].
Both factors might interfere with spectrophotometer detec-
tion and result in false-positive values.
To conﬁrm our results, the activation of PMNs was ana-
lyzed via the forward scatter (FSC) intensity, which indicates
an increase in cell volume upon activation. Again, positively
charged PLL-coated nanoparticles resulted in an increase in
the PMN volume most likely due to a phagocytic response
[63]. Our results align with a study conducted by Fattorossi
et al. [63], demonstrating an increase in neutrophil cell size
by FACS upon PMA treatment. On the other hand, the
neutral and negatively charged particles PEG and PVA,
respectively, did not lead to an increase in FSC; hence, no
internalization occurred. If we compare the percentage of
PMA-stimulated WBCs with that of the PLL treated, we will
notice that both gave similar eﬀect in the NFT results but dif-
fered in the ﬂow cytometry analysis. This could be attributed
to several factors, including (a) NFT screened only for neu-
trophils while ﬂow cytometry histograms plotted all PMNs,
(b) neutrophils with formazan deposits on the cell surface
might score on an NFT but result in smaller size in ﬂow
cytometry due to its bursting status, and (c) PMA might be
less cytotoxic than PLL to cells.
Interestingly, the diﬀerence in Z-potential of AuNPs
prior to plasma incubation was no longer present in the
AuNPs.protein complexes (Figure 3(b)). PLL-coated NPs lost
their positivity and became nearly neutral. This inspired us to
run 1-D gel electrophoresis and DLS to identify whether
protein adsorption is the major contributor in neutralizing
the PLL charges. Electrophoretic separation of plasma pro-
teins from our polymer-coated NPs showed comparable
adsorption of proteins on PVA and PLL nanoparticles
(Figure 3(c)); however, minimal binding of plasma proteins
was detected on PEGylated PLL-AuNP particles. This result
is in line with a previous study showing that positively and
negatively charged AuNPs incubated with human plasma
resulted in a wide range of protein binding unlike the nearly
neutral charged particles [66]. Our results support as well
another study by Hühn et al. [67] reporting a comparable
amount of bound plasma proteins on positively and nega-
tively charged particles. The same group also tested cellular
uptake of polymer-coated AuNPs and demonstrated that
despite similar binding adsorption on both polymer-coated
AuNPs, positively charged AuNPs are taken up faster by cells,
thus pointing to the sign of charge as a major indicator in
mediating internalization. It is worth noting that in our study,
we used diﬀerent compositions of polymers to coat our NPs,
without any addition of conjugated ﬂuorophores. We also
used whole blood instead of cultured ﬁbroblast cell lines,
and yet we conﬁrm the microscopic observation by Hühn
et al. of higher rate of cellular uptake for positively charged
NPs. Overall, the sign of NPs is prone to Z-potential shifts
once in the blood circulation due to protein corona formation.
In our case, a shift of ~+6mV, ~−12mV, and ~−30mV was
detected for PVA-, PEG-, and PLL-AuNPs, respectively.
Interestingly, nearly neutralized PLL-AuNPs.protein com-
plexes favored a faster activation of neutrophils compared to
the negative and PEGylated NPs. This is most likely due to
the change in the NPs’ sizes as observed by our DLS measure-
ments (Figure 3(a)). The highest increase of more than
200 nmwas detected for positively charged PLL-AuNPs while
the PEGylated PLL-AuNPs increased only by about 13 nm.
Thus, aside from NPs’ charge and aﬃnity to protein adsorp-
tion, what mainly makes the diﬀerence in neutrophil activa-
tion is the NPs’ size.
Therefore, our data supports the surface charge as the
major determinant in attracting plasma proteins to the sur-
face coat of the nanoparticles and consequently changing
their size. The size and shape in turn are known to aﬀect
the rate of cellular uptake [68, 69]. Nearly neutral PEGylated
NPs exhibit lower aﬃnity to plasma proteins, thus reducing
their size and consequently their cellular uptake, not to forget
that neutrally charged NPs have less electrostatic interactions
to the net negatively charged plasma membrane than do pos-
itive NPs, thereby reducing their uptake [70]. This supports
other ﬁndings in the literature pointing to the use of neutral
NPs (speciﬁcally PEGylated NPs) as promising agents in
drug delivery [71] due to their prolonged lifetime in the
blood [72, 73].
However, the inability of PEG- and PVA-coated NPs
to elicit a signiﬁcant immune response does not mean that
AuNPs are fully inert from the immunological point of
view. Such linkers might hydrolyze and degrade after an
extended applied period forming metabolites or tissue
lesions. This in turn might alert the immune system and
trigger inﬂammation.
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Finally, our simple method to identify the behavior of
NPs in blood aliquots is quick and eﬀective and could facili-
tate the immunological screening of various NPs prior to
clinical applications. Next, we hope to examine the in vivo
biodistribution of our synthesized neutral PEGylated AuNPs
and their ability to be cleared in the urine or other excretory
pathways [74].
4. Conclusions
It is undeniable that the future holds promising advances
concerning the safe biodistribution and immune evasion of
engineered nanoparticles. For the ﬁrst time, this paper shows
compelling evidence that reveals the immunogenic nature of
charged AuNPs through the use of a novel yet simple
method. Our results support the absence of a signiﬁcant
inﬂammatory activity associated with our designed gold
nanoparticles, particularly PLL-AuNPs and PEG-AuNPs.
Thus, such NPs serve as promising vehicles to be used for
ligand or drug delivery in chronic infections, cancer treat-
ment, and immunotherapeutic approaches.
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